XML 27 R11.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Agenus Royalty Purchase Agreement | 12 Months Ended
--- | ---
Dec. 31, 2018
Royalty Purchase Agreement [Abstract] |
Agenus Royalty Purchase Agreement | 5. Agenus Royalty Purchase Agreement On September 20, 2018, the Company entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”) with Agenus. Under the Royalty Purchase Agreement, the Company purchased from Agenus the right to receive 33% of the future royalties on six Incyte immuno-oncology assets, currently in development, due to Agenus from Incyte Europe Sarl (“Incyte”) (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into the clinical trials. The future royalties due to Agenus from Incyte are based on low-single to mid-teen digit percentage of applicable net sales. In addition, the Company purchased from Agenus the right to receive 33% of the future royalties on an undisclosed Merck immuno-oncology product currently in clinical development due to Agenus from Merck Sharp & Dohme Corp. (“Merck”) and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single digit percentage of applicable net sales. Pursuant to the Royalty Purchase Agreement, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements. Under the terms of the Royalty Purchase Agreement, the Company paid Agenus $15.0 million. The Company financed $7.5 million of the purchase price with a term loan under its Loan and Security Agreement with Silicon Valley Bank (“SVB”) (see Note 9). As of December 31, 2018, the Company recorded $15.0 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment of $15.0 million has been fully collected.

X
- Definition Royalty purchase agreement. + References No definition available. + Details
Name: | xoma_RoyaltyPurchaseAgreementAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty purchase agreement. + References No definition available. + Details
Name: | xoma_RoyaltyPurchaseAgreementTextBlock
Namespace Prefix: | xoma_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration